Strength and endurance measures
Some selected measures improved in an uncontrolled study of older men. Without a comparison group, the treatment's contribution remains uncertain.
Read the publication
Physician-led care in the UAE
Peptide care · Pen
Sermorelin
A small human study found changes in growth-hormone secretion and selected strength measures, with no change in body composition.
- Discuss your health goals and suitability with a physician
- Your prescribed preparation is confirmed during care
- Clinical review and follow-up guide the next steps
Select the format
Get startedImportant safety informationSuitability reviewed by a UAE-licensed physician
Confirm the dispensing pharmacy and preparation before treatment
Completing an assessment does not guarantee a prescription
Formats reflect the supplied catalog, not a prescription or confirmation of availability. Health topics describe scientific interest, not approved indications. Read the specific studies and preparation limits.
The role of this peptide
Where Sermorelin
has been studied.
Studied in relation to growth-hormone signaling in older men. It does not establish a general anti-aging or exercise-recovery benefit.
Body composition
The same short study did not find a change in body composition. It does not establish a general anti-aging or muscle-building benefit.
Read the publicationSafety & suitability
Is Sermorelin right for you?
Small, short studies provide limited information about longer-term benefit and risk. Discuss hormone-related monitoring and your medical history.
Suitability depends on the specific preparation, intended use and clinical assessment. Product authorization must be verified separately from facility licensing.
The evidence
Sermorelin:
what has been studied.
A small uncontrolled study reported changes in some strength measures, but not body composition. Broader muscle-building or anti-aging benefits remain uncertain.
Growth-hormone secretion and some strength or endurance measures increased over six weeks.
11 men aged 64–76 · Subcutaneous
What remains uncertain
Read the studyThere was no control group; only selected performance measures improved and body composition did not change.
About this evidence review
The cited paper studied GHRH 1-29, relevant to sermorelin. Studies of other modified GHRH analogs should not be treated as identical evidence.
Reviewed September 15, 2026. Selected publications, not a systematic review. Findings do not establish product authorization.
Our review approachFor your consultation
Know what to ask.
Three questions to help you discuss Sermorelin. Your clinician decides which preparation, checks and follow-up are relevant.
01
The preparation
What exactly are we considering?
What is the exact ingredient, formulation and strength, and how would it be used?
02
Your assessment
What needs checking first?
Would IGF-1 and thyroid function (TSH) be relevant to my baseline assessment?
03
Your follow-up
How will we review the plan?
What would count as a meaningful benefit, when would we review it, and which side effects should I report?
These questions are not a dosing schedule or a required test panel. Your clinician individualizes the plan.
A considered approach
to peptide care.
A peptide name is only the beginning. The preparation, clinical need and available evidence all matter to the decision.
Dr. Sami Mohammed Yesuf, MD
Medical Director & Physician, DarDoc
Dr. Marwa Abuaita, MD
Physician, DarDoc
- 01
Start with the clinical question
Discuss the symptoms or diagnosis behind your interest in a peptide, alongside current medicines and previous treatment.
- 02
Review the exact preparation
Consider the evidence for its route and intended use, its regulatory status, and established treatment alternatives.
- 03
Make an informed decision
Discuss potential benefits, uncertainties and risks. A prescription is considered only when clinically appropriate and permitted.
- 04
Agree how to review progress
If treatment is prescribed, agree on monitoring, side effects to report and when to reassess the plan.
SCOPE credentials shown relate to obesity medicine, not peptide-specific certification. The treating physician is confirmed at booking.
A few things to know
Your questions,
answered.
How is Sermorelin considered in a consultation?
Your physician reviews your symptoms, history, current medicines and goals. The discussion should include the specific evidence, risks, alternatives and a follow-up plan before any treatment decision.
Which Sermorelin format is right for me?
The cited paper studied GHRH 1-29, relevant to sermorelin. Studies of other modified GHRH analogs should not be treated as identical evidence.
What should I know about the safety of Sermorelin?
Small, short studies provide limited information about longer-term benefit and risk. Discuss hormone-related monitoring and your medical history.
Can I order without a consultation?
Prescription treatment is considered only after clinical assessment. Browsing a format does not select a dose, determine eligibility or guarantee a prescription.
Continue exploring
More in this area.
Explore other compounds discussed in these health topics, with the evidence for each.
DarDoc peptidesRecovery · Skin & hair · Digestive health
BPC-157
Early human reports describe improvements in specific pain and bladder conditions. The preparation and treatment site matter.
DarDoc peptidesRecovery · Skin & hair
Thymosin Beta-4
The studies reviewed here examined wound healing and short-term tolerability. Their findings apply to the preparations and outcomes studied.
DarDoc peptidesHealthy aging · Sleep & focus
Epitalon
Cell studies examine telomerase activity. An older clinical report explored a retinal condition, but human longevity benefits remain unestablished.
Bring your questions
Make your next step
a conversation.
Want to understand where Sermorelin fits? Discuss the evidence, your health history and the options with DarDoc.
